Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Holding ARVN?
Track your performance easily
ARVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.17 - $53.08
Previous Close$25.86
Volume496.21K
Average Volume (3M)562.45K
Market Cap
$1.78B
Enterprise Value$656.82M
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 03, 2025EPS Estimate
-$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding68,713,098
10 Day Avg. Volume758,704
30 Day Avg. Volume562,450
Standard Deviation0.39
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.66
Price to Sales (P/S)9.23
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit8.37
Enterprise Value/Ebitda-2.05
Forecast
1Y Price Target
$62.27Price Target Upside147.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Arvinas Holding Company News
PremiumCompany Announcements
Arvinas Reports Progress in Q3 2024 Financials and Trials
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVERITAC-2 will evaluate vepdegestrant (vepdeg) monotherapy in 2L+ ER+/HER2- breast cancer vs a fulvestrant control arm, with the potential to show activity in ESR1 WT patients who are still endocrine sensitive.
Market PotentialVepdeg palbo combination data sets precedent for the rest of combination studies given the wide compatibility of vepdeg with different inhibitors.
Safety And EfficacyThe 'full dose' of both agents demonstrated a manageable safety profile, suggesting there were no drug-drug interactions observed.
Bears Say
Clinical TrialsThe readout is unlikely to provide progression-free survival in ESR1 WT patients.
Stock PerformanceShares are down -30% YTD as investors remain concerned about vepdeg's combinability and toxicity.
Study DesignThe VERITAC-2 study is not powered to detect statistical significance in the ESR1-wild-type population.
---
Ownership Overview
2.66% Insiders
24.79% Mutual Funds
47.88% Other Institutional Investors
9.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $21.17 and its highest was $53.08 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Currently, no data Available
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Mar 03, 2025 which is in 97 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Oct 30, 2024. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.843 by $0.163.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -$1.03.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,713,100 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.843. Following the earnings report the stock price went up 0.582%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Among the largest hedge funds holding Arvinas Holding Company’s share is New Leaf Venture Partners, L.L.C.. It holds Arvinas Holding Company’s shares valued at 35M.
---
Arvinas Holding Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.27 (147.59% Upside)
$62.27 (147.59% Upside)
Hedge Fund Trend
Increased
By 551.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.78%
12-Months-Change
Fundamentals
Return on Equity
-59.16%
Trailing 12-Months
Asset Growth
10.28%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Earnings Call
Q3 2024
0:00 / 0:00
---
ARVN Stock 12 Month Forecast
Average Price Target
$62.27
▲(147.59% Upside)
Technical Analysis
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+17.91%
reiterated a buy rating 6 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +17.91% per trade.
---